Difference between revisions of "Main Page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 10: Line 10:
 
|colspan="2" style="background-color:#F0F0F0"|'''[[Tutorial#Variant|Regimen variants]]:<big> {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}</big>'''
 
|colspan="2" style="background-color:#F0F0F0"|'''[[Tutorial#Variant|Regimen variants]]:<big> {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}</big>'''
 
|-
 
|-
−
|style="width: 25%; border-left:solid 20px #3182bd"|[[#solidtumors|Solid Tumors]]  
+
|style="width: 25%; border-left:solid 20px #3182bd; background-color:#deebf7"|[[#solidtumors|Solid Tumors]]  
−
|style="width: 25%; border-left:solid 20px #de2d26"|[[#malignantheme|Malignant Hematology]]
+
|style="width: 25%; border-left:solid 20px #de2d26; background-color:#fee0d2"|[[#malignantheme|Malignant Hematology]]
−
|style="width: 25%; border-left:solid 20px #756bb1"|[[#transplant|Transplant]]
+
|style="width: 25%; border-left:solid 20px #756bb1; background-color:#efedf5"|[[#transplant|Transplant]]
−
|style="width: 25%; border-left:solid 20px #31a354"|[[#otherheme|Other Hematology]]
+
|style="width: 25%; border-left:solid 20px #31a354; background-color:#e5f5e0"|[[#classicalheme|Classical Hematology]]
 
|-
 
|-
 
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]'''
 
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]'''
Line 35: Line 35:
 
|colspan="4" style="background-color:#9ecae1"|'''Breast Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Breast Oncology'''
 
|-
 
|-
−
|colspan="2" style="background-color:#deebf7"|[[Breast cancer]]
+
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Breast cancer]]
−
|colspan="2" style="background-color:#deebf7"|[[Breast cancer, HER-2 positive]]
+
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Breast cancer, HER-2 positive]]
 
|-
 
|-
 
|colspan="4" style="background-color:#9ecae1"|'''Dermatologic Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Dermatologic Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Melanoma]]  
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Melanoma]]  
−
|style="background-color:#deebf7"|[[Basal cell and squamous cell skin cancer | Skin, basal & squamous cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Basal cell and squamous cell skin cancer | Skin, basal & squamous cancer]]
−
|style="background-color:#deebf7"|[[Merkel cell carcinoma]]  
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Merkel cell carcinoma]]  
−
|style="background-color:#deebf7"|
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
 
|-
 
|-
 
|colspan="4" style="background-color:#9ecae1"|'''Endocrine Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Endocrine Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Germ cell tumors]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Germ cell tumors]]
−
|style="background-color:#deebf7"|[[Neuroendocrine tumors]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Neuroendocrine tumors]]
−
|style="background-color:#deebf7"|[[Thyroid cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Thyroid cancer]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
 
|colspan="4" style="background-color:#9ecae1"|'''Gastrointestinal Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Gastrointestinal Oncology'''
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Anal cancer]]
+
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Anal cancer]]
−
|style="width: 25%; background-color:#deebf7"|[[Colon cancer]]
+
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Colon cancer]]
−
|style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]]
+
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Esophageal cancer]]
−
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer]]
+
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Gastric cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
+
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
−
|style="width: 25%; background-color:#deebf7"|[[Hepatobiliary cancer]]
+
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Hepatobiliary cancer]]
−
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer]]  
+
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Pancreatic cancer]]  
−
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]]
+
|style="width: 25%; border-left:solid 10px #3182bd; background-color:#deebf7"|[[Rectal cancer]]
 
|-
 
|-
 
|colspan="4" style="background-color:#9ecae1"|'''Genitourinary Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Genitourinary Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Bladder cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Bladder cancer]]
−
|style="background-color:#deebf7"|[[Germ cell tumors]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Germ cell tumors]]
−
|style="background-color:#deebf7"|[[Penile cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Penile cancer]]
−
|style="background-color:#deebf7"|[[Prostate cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Prostate cancer]]
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Renal cancer|Renal cancer (RCC)]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Renal cancer|Renal cancer (RCC)]]
−
|style="background-color:#deebf7"|[[Testicular cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Testicular cancer]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
Line 78: Line 78:
 
|colspan="4" style="background-color:#9ecae1"|'''Gynecologic Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Gynecologic Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Cervical cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Cervical cancer]]
−
|style="background-color:#deebf7"|[[Germ cell tumors]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Germ cell tumors]]
−
|style="background-color:#deebf7"|[[Ovarian cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Ovarian cancer]]
−
|style="background-color:#deebf7"|[[Uterine cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Uterine cancer]]
 
|-
 
|-
 
|colspan="4" style="background-color:#9ecae1"|'''Head & Neck Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Head & Neck Oncology'''
 
|-
 
|-
−
|colspan="2" style="background-color:#deebf7"|[[Head and neck cancer]]
+
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Head and neck cancer]]
−
|colspan="2" style="background-color:#deebf7"|[[Thyroid cancer]]
+
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Thyroid cancer]]
 
|-
 
|-
 
|colspan="4" style="background-color:#9ecae1"|'''Neuro-Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Neuro-Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Central nervous system (CNS) cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Central nervous system (CNS) cancer]]
−
|style="background-color:#deebf7"|[[Glioblastoma]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Glioblastoma]]
−
|style="background-color:#fee0d2"|[[CNS leukemia]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[CNS leukemia]]
−
|style="background-color:#fee0d2"|[[CNS lymphoma]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[CNS lymphoma]]
 
|-
 
|-
 
|colspan="4" style="background-color:#9ecae1"|'''Pediatric Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Pediatric Oncology'''
 
|-
 
|-
−
|colspan="4" style="background-color:#deebf7"|[[Neuroblastoma]]
+
|colspan="4" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Neuroblastoma]]
 
|-
 
|-
 
|colspan="4" style="background-color:#9ecae1"|'''Sarcoma'''
 
|colspan="4" style="background-color:#9ecae1"|'''Sarcoma'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Bone cancer]]  
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Bone cancer]]  
−
|style="background-color:#deebf7"|[[Ewing's sarcoma]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Ewing's sarcoma]]
−
|style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
−
|style="background-color:#deebf7"|[[Osteosarcoma]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Osteosarcoma]]
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Sarcoma]]  
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Sarcoma]]  
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
Line 113: Line 113:
 
|colspan="4" style="background-color:#9ecae1"|'''Thoracic Oncology'''
 
|colspan="4" style="background-color:#9ecae1"|'''Thoracic Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Esophageal cancer]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Esophageal cancer]]
−
|style="background-color:#deebf7"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]]
−
|style="background-color:#deebf7"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]]
−
|style="background-color:#deebf7"|[[Mesothelioma]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Mesothelioma]]
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Thymoma]]
+
|style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Thymoma]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
Line 125: Line 125:
 
|colspan="4" style="background-color:#9ecae1"|'''Site-agnostic'''
 
|colspan="4" style="background-color:#9ecae1"|'''Site-agnostic'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[MSI-H or dMMR]]
+
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[MSI-H or dMMR]]
−
|style="background-color:#deebf7"|[[Unknown primary]]
+
|colspan="2" style="border-left:solid 10px #3182bd; background-color:#deebf7"|[[Unknown primary]]
−
|style="background-color:#deebf7"|
 
−
|style="background-color:#deebf7"|
 
 
|-
 
|-
 
|}
 
|}
Line 141: Line 139:
 
|colspan="4" style="background-color:#fc9272"|'''Acute leukemias'''
 
|colspan="4" style="background-color:#fc9272"|'''Acute leukemias'''
 
|-
 
|-
−
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
+
|style="width: 25%; border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
−
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
+
|style="width: 25%; border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
−
|style="width: 25%; background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
+
|style="width: 25%; border-left:solid 10px #de2d26; background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
−
|style="width: 25%; background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)]]
+
|style="width: 25%; border-left:solid 10px #de2d26; background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)]]
 
|-
 
|-
 
|colspan="4" style="background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
 
|colspan="4" style="background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
−
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
−
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
−
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Myelodysplastic syndrome]]
−
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
−
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
−
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Systemic mastocytosis]]
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Mature B-, T-, and NK-cell neoplasms'''
+
|colspan="4" style="background-color:#fc9272"|'''Aggressive lymphomas'''
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
−
|style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[CNS lymphoma]]
−
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
−
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | Chronic lymphocytic leukemia (CLL/SLL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[HIV-associated lymphoma]]
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[CNS lymphoma]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]]  
−
|style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
−
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
−
|style="background-color:#fee0d2"|[[Extranodal NK/T-cell lymphoma, nasal type]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
−
|style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
+
|style="background-color:#fee0d2"|
−
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
+
|style="background-color:#fee0d2"|
−
|style="background-color:#fee0d2"|[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]]
+
|style="background-color:#fee0d2"|
 +
|-
 +
|colspan="4" style="background-color:#fc9272"|'''Indolent lymphomas'''
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | Chronic lymphocytic leukemia (CLL/SLL)]]
−
|style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
−
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
−
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
−
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
−
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (MM)]]
+
|style="background-color:#fee0d2"|
−
|style="background-color:#fee0d2"|[[NK/T-cell lymphoma]]
+
|style="background-color:#fee0d2"|
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
+
|colspan="4" style="background-color:#fc9272"|'''Plasma cell dyscrasias'''
−
|style="background-color:#fee0d2"|[[Plasma cell leukemia]]
 
−
|style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
−
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
 
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
−
|style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
+
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (MM)]]
 +
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Plasma cell leukemia]]
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 +
|-
 +
|colspan="4" style="background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
 +
|-
 +
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
 +
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
 +
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
 +
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Extranodal NK/T-cell lymphoma, nasal type]]
 +
|-
 +
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
 +
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[NK/T-cell lymphoma]]
 +
|style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 +
|-
 +
|colspan="4" style="background-color:#fc9272"|'''Lymphoproliferative disorders'''
 +
|-
 +
|colspan="2" style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Castleman disease]]
 +
|colspan="2" style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 +
|-
 +
|colspan="4" style="background-color:#fc9272"|'''Histiocyte disorders'''
 +
|-
 +
|colspan="2" style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis (HLH)]]
 +
|colspan="2" style="border-left:solid 10px #de2d26; background-color:#fee0d2"|[[Histiocytoses]]
 
|-
 
|-
 
|}
 
|}
Line 204: Line 223:
 
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#756bb1"|'''Transplant'''
 
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#756bb1"|'''Transplant'''
 
|-
 
|-
−
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]]
+
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Stem cell mobilization]]
−
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT conditioning regimens]]
+
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Allogeneic HSCT conditioning regimens]]
−
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT conditioning regimens]]
+
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Autologous HSCT conditioning regimens]]
−
|style="width: 25%; background-color:#efedf5"|[[Graft versus host disease (GVHD)]]
+
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Graft versus host disease (GVHD)]]
 
|-
 
|-
 
|}
 
|}
−
<span id="otherheme"></span>
+
<span id="classicalheme"></span>
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
|-
 
|-
Line 216: Line 235:
 
|}
 
|}
 
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
−
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Other Hematology'''
+
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
−
|-
 
−
|style="width: 25%; background-color:#e5f5e0"|[[Aplastic anemia]]
 
−
|style="width: 25%; background-color:#e5f5e0"|[[Atypical hemolytic-uremic syndrome (aHUS)]]
 
−
|style="width: 25%; background-color:#e5f5e0"|[[Autoimmune cytopenias]]
 
−
|style="width: 25%; background-color:#e5f5e0"|[[Autoimmune thrombocytopenic purpura (ITP)]]
 
 
|-
 
|-
−
|style="background-color:#e5f5e0"|[[Castleman disease]]
+
|style="width: 25%; border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Aplastic anemia]]
−
|style="background-color:#e5f5e0"|[[Coagulopathies]]
+
|style="width: 25%; border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Atypical hemolytic-uremic syndrome (aHUS)]]
−
|style="background-color:#e5f5e0"|[[Cold agglutinin disease]]
+
|style="width: 25%; border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Autoimmune cytopenias]]
−
|style="background-color:#e5f5e0"|[[Hemophagocytic lymphohistiocytosis (HLH)]]
+
|style="width: 25%; border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Autoimmune thrombocytopenic purpura (ITP)]]
 
|-
 
|-
−
|style="background-color:#e5f5e0"|[[Histiocytoses]]
+
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Coagulopathies]]
−
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria (PNH)]]
+
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Cold agglutinin disease]]
−
|style="background-color:#e5f5e0"|[[Sickle cell anemia]]
+
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria (PNH)]]
−
|style="background-color:#e5f5e0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]]
+
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Sickle cell anemia]]
 
|-
 
|-
−
|style="background-color:#e5f5e0"|[[Venous thromboembolism (VTE)]]
+
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]]
−
|style="background-color:#e5f5e0"|
+
|style="border-left:solid 10px #31a354; background-color:#e5f5e0"|[[Venous thromboembolism (VTE)]]
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|

Revision as of 19:30, 10 October 2017

HemOnc.org - A Free Hematology/Oncology Reference

Regimens: 4,434 Regimen variants: 6,583
Solid Tumors Malignant Hematology Transplant Classical Hematology
Mobile Version Editorial Board Desktop Version
Disease index Drug index Regimen index General reference
If this is your first time visiting, please go to the tutorial page or just start exploring!

Links to Main Disease Pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, HER-2 positive
Dermatologic Oncology
Melanoma Skin, basal & squamous cancer Merkel cell carcinoma Cutaneous T-cell lymphoma (CTCL)
Endocrine Oncology
Germ cell tumors Neuroendocrine tumors Thyroid cancer
Gastrointestinal Oncology
Anal cancer Colon cancer Esophageal cancer Gastric cancer
Gastrointestinal stromal tumor (GIST) Hepatobiliary cancer Pancreatic cancer Rectal cancer
Genitourinary Oncology
Bladder cancer Germ cell tumors Penile cancer Prostate cancer
Renal cancer (RCC) Testicular cancer
Gynecologic Oncology
Cervical cancer Germ cell tumors Ovarian cancer Uterine cancer
Head & Neck Oncology
Head and neck cancer Thyroid cancer
Neuro-Oncology
Central nervous system (CNS) cancer Glioblastoma CNS leukemia CNS lymphoma
Pediatric Oncology
Neuroblastoma
Sarcoma
Bone cancer Ewing's sarcoma Gastrointestinal stromal tumor (GIST) Osteosarcoma
Sarcoma
Thoracic Oncology
Esophageal cancer Lung cancer, non-small cell (NSCLC) Lung cancer, small cell (SCLC) Mesothelioma
Thymoma
Site-agnostic
MSI-H or dMMR Unknown primary

back to top
Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) B-cell acute lymphoblastic leukemia (B-ALL) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myelogenous leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma CNS lymphoma Diffuse large B-cell lymphoma (DLBCL) HIV-associated lymphoma
Hodgkin lymphoma (HL) Mantle cell lymphoma (MCL) Mediastinal gray-zone lymphoma (MGZL) Primary mediastinal B-cell lymphoma (PMBL)
Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (MM) Plasma cell leukemia
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK/T-cell lymphoma, nasal type
Large granular lymphocytic (LGL) leukemia NK/T-cell lymphoma Peripheral T-cell Lymphoma (PTCL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocyte disorders
Hemophagocytic lymphohistiocytosis (HLH) Histiocytoses

back to top
Transplant
Stem cell mobilization Allogeneic HSCT conditioning regimens Autologous HSCT conditioning regimens Graft versus host disease (GVHD)

back to top
Classical Hematology
Aplastic anemia Atypical hemolytic-uremic syndrome (aHUS) Autoimmune cytopenias Autoimmune thrombocytopenic purpura (ITP)
Coagulopathies Cold agglutinin disease Paroxysmal nocturnal hemoglobinuria (PNH) Sickle cell anemia
Thrombotic thrombocytopenic purpura (TTP) Venous thromboembolism (VTE)
Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100s of hematology/oncology drugs, and 1000s of antineoplastic regimens. Content is added by hematology & oncology providers, and undergoes continuous peer review.


Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details. Priorities of this project include:

  1. Creating a database of chemotherapy agents and other medications.
  2. Creating a database of chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
  3. Sample order sets and examples of supportive medications used with treatment regimens
  4. Aggregating useful links to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.

Additional possibilities for this project may include:

  1. Creating summaries of pivotal clinical trials
  2. Establishing homepages for ongoing clinical trials that contain information and sites of participation
  3. Checklists for common clinical scenarios/diseases
  4. Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.

Retrieved from "https://hemonc.org/w/index.php?title=Main_Page&oldid=17901"